19th Jul 2019 10:37
(Alliance News) - Neuroscience technology company Cambridge Cognition Holdings PLC said it has secured a second commercial partnership with an undisclosed pharmaceutical company for its NeuroVocalix product.
Shares in the company rose 9.7% at 62.00 pence each in London on Friday morning.
The unnamed pharmaceutical company will trial the NeuroVocalix technology, which enables patients to receive voice-based cognitive assessments through mobile platforms, Cambridge Cognition said.
The company signed its first commercial deal for the product, in September 2018. It received funds for the platform from Innovate UK, an agency of the Department for Business, Energy & Industrial Strategy, in March 2018.
Chief Executive Matthew Stork said: "We are delighted to have received an order from a leading pharmaceutical company to trial the NeuroVocalix platform. We are also very pleased with the results from the work funded by Innovate UK, which enabled us to complete vital validation work."
"Providing automated verbal testing and at the same time identifying voice biomarkers during clinical trials could help accelerate and improve the quality of clinical trials, benefiting patients across the world and providing a major opportunity for Cambridge Cognition," Stork added.
Related Shares:
Cambridge Cog